Skip to content

lab services

Services for SARS-COV-2
Drug Development

Experience and expertise for inhaled drug therapies and vaccines

Over a million people worldwide are now suffering from symptoms caused by the novel SARS-CoV-2 (aka COVID-19) virus. As the number of those affected continues to soar, researchers are working tirelessly to find effective therapies and vaccines.

Many pharmaceutical and biotech companies are well underway in developing new therapies or initiating studies to repurpose existing drugs for the potential treatment of SARS-CoV-2. Recently, the US FDA pledged its support of this effort by announcing the Coronavirus Treatment Acceleration Program (CTAP), promising to utilize every available method to move new treatments to patients as quickly as possible, while at the same time finding out whether they are helpful or harmful.

Orally inhaled drug products have a long history of treating respiratory disease. Common dosage forms include nebulizers, dry powder inhalers (DPI), pressured metered dose inhalers (pMDI), and soft mist inhalers (SMI). Each offer their own benefits and advantages. In addition, treatment via the nasal cavity is also a popular target area to deliver vaccines and other systematic drugs.

Proveris has more than 25 years’ experience in orally inhaled and nasal drug products (OINDPs), specializing in human realistic in vitro characterization and thriving to improve the correlation between in vitro and in vivo studies. We would like to extend our experience and expertise to developing therapies and vaccines for SARS-CoV-2. Contact us to learn how we can help you with:

Access current, relevant resources for respiratory drug development & quality control.

Optimize your workflow with our complete suite of testing solutions and technologies.

See study results that informed decision making and success

request a callback

From a Proveris Sales Associate